Home Daily Intelligence Tracker
    • Plans Blog Contact
    Autolus Therapeutics Ltd logo
    AUTL

    Autolus Therapeutics Ltd

    MaveScore 18 Low model confidence
    Last Price US$1.61 As of Jul 10, 2026
    Market Cap US$428.5m Company size context
    7D Performance 1.90% Past 7 days
    1Y Performance -34.82% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    103 days old

    Market price date

    Jul 10, 2026

    2 days old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 18 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    10/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    0/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    2/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    6/15 Weak

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Autolus Therapeutics Ltd Overview

    Industry: Biotechnology

    Sector: Healthcare

    Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial Read More

    Autolus Therapeutics Ltd is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Autolus Therapeutics Ltd

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 14, 2026

    Quarterly result summary

    Revenue was $26.2M (+191% YoY). Net loss was -$71.6M (from $70.2M). Cash was $229.4M.

    Revenue $26.2M +191% YoY
    Net loss -$71.6M from $70.2M
    Cash $229.4M reported

    What changed

    • Revenue +191% YoY to $26.2M.
    • Net loss was -$71.6M (from $70.2M).

    Guidance / outlook

    we expect continued improvement as we grow sales and manage costs,” said Dr.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 14, 2026 Earnings release Earnings release May 14, 2026 SEC filing 10-K Mar 27, 2026 Earnings release Earnings release Mar 27, 2026 Earnings release Earnings release Mar 27, 2026 Earnings release Earnings release Nov 12, 2025 Earnings release Earnings release Nov 12, 2025 SEC filing 10-Q Nov 12, 2025 SEC filing 10-Q Aug 12, 2025 Earnings release Earnings release Aug 12, 2025 Earnings release Earnings release Aug 12, 2025

    Recent News



    AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK
    3 hours ago
    Autolus (Nasdaq: AUTL) to Launch AUCATZYL on NHS in England and Wales After NICE Backing
    6 hours ago
    Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of “Moderate Buy” by Brokerages
    Yesterday

    Earnings Per Share

    Score 5.00/5
    Autolus Therapeutics Ltd boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 1.07/5
    Autolus Therapeutics Ltd exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Autolus Ther... AUTL US$428.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 0.35/5
    Autolus Therapeutics Ltd olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Autolus Ther... AUTL US$428.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 2.57/5
    Autolus Therapeutics Ltd attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Autolus Ther... AUTL US$428.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Autolus Therapeutics Ltd logo

    Autolus Therapeutics Ltd

    US$1.61

    US$428.5m

    1.90%

    -34.82%